Metropolis Healthcare Q1 Results FY27: PAT at Rs 50 Cr for June 2026 Quarter
- August 5, 2026
- Posted by: Ankit Jaiswal
- Category: News
Metropolis Healthcare Q1 results FY27: PAT Rs 50 Cr (+42.16% YoY) | Revenue Rs 372 Cr (+15.03% YoY) | Gross Margin 17.5% | Stock Rs 584.5 (down 2.00%)
The Metropolis Healthcare Q1 results FY27 show standalone revenue of Rs 372 Cr for the quarter ended 30 June 2026, +15.03% year on year from Rs 323 Cr in Q1 FY26, as Metropolis Healthcare reported its numbers on 4 August 2026. Metropolis Healthcare posted pat of Rs 50 Cr for the quarter, against Rs 35 Cr in Q1 FY26, a change of +42.16%. Shares traded around Rs 584.5 on the NSE, down 2.00% on the day.
India’s healthcare sector is in a structural multi-year upcycle, driven by rising insurance penetration, government schemes expanding hospital access to Tier-2 and Tier-3 cities, and growing chronic disease management demand. Hospitals that can sustain occupancy above 70% and hold Average Revenue Per Occupied Bed (ARPOB) steady are typically rewarded with operating efficiency gains flowing through to the bottom line. Against that backdrop, the Metropolis Healthcare Q1 results FY27 give investors the first hard data point for FY27. This article breaks down what happened at the revenue, gross profit, and net profit line, what the numbers mean for the full year, and what questions investors should be asking before making any portfolio decision.
Click Here – Get Free Investment Predictions
Metropolis Healthcare Q1 results FY27 Financial Highlights
All figures are standalone numbers in Rs Crore as reported by Metropolis Healthcare for Q1 FY27 (April to June 2026). The table compares them against the same quarter in FY26.
| Metric | Q1 FY27 (Jun 2026) | Q1 FY26 (Jun 2025) | YoY Change |
|---|---|---|---|
| Revenue | Rs 372 Cr | Rs 323 Cr | +15.03% |
| Gross Profit | Rs 65 Cr | Rs 49 Cr | +34.08% |
| Gross Profit Margin | 17.5% | 15.2% | +2.3 pts |
| Net Profit (PAT) | Rs 50 Cr | Rs 35 Cr | +42.16% |
| Net Profit Margin | 13.4% | 10.8% | +2.6 pts |
Metropolis Healthcare Q1 results FY27 Performance Analysis
Metropolis Healthcare delivered steady topline progress this quarter. Revenue grew +15.03% year on year to Rs 372 Cr, against Rs 323 Cr in Q1 FY26. The growth is organic and in line with the company’s stated ambitions for FY27, suggesting the business is executing broadly on plan.
Operating profitability showed positive momentum this quarter. Gross profit grew +34.08% to Rs 65 Cr (17.5% margin) from Rs 49 Cr a year earlier, outpacing revenue growth and signalling cost discipline or a favourable product mix.
Net profit (pat) came in at Rs 50 Cr, up +42.16% year on year from Rs 35 Cr. Double-digit earnings growth in combination with topline expansion is the ideal outcome for investors tracking this stock for its compounding potential.
Check the Univest Screener for Live Data
Metropolis Healthcare Q1 results FY27: Key Business Factors
1. Revenue: What Drove the Quarter
Metropolis Healthcare reported revenue of Rs 372 Cr against Rs 323 Cr in Q1 FY26, a change of +15.03%. Understanding this revenue figure requires context: in the healthcare sector, volume growth and realisation per unit are both drivers, and the aggregate revenue number is the product of both. Investors tracking Metropolis Healthcare should check the investor presentation or earnings call commentary for the volume-versus-pricing split underlying this quarter’s topline.
2. Gross Profit and Margin Trends
Gross margin improved to 17.5% from 15.2% in Q1 FY26, a gain of 2.3 percentage points. This expansion signals that Metropolis Healthcare has either improved its procurement costs, shifted to higher-margin products, or benefited from softer input prices in the healthcare sector. Margin expansion sustained over multiple quarters is typically a strong driver of earnings upgrades and re-rating.
3. Net Profit and Earnings Quality
Metropolis Healthcare posted pat of Rs 50 Cr for the June 2026 quarter, against Rs 35 Cr in Q1 FY26, a change of +42.16%. This bottom line figure is what drives earnings per share and, ultimately, the P/E multiple at which the stock trades. Analysts will now update their FY27 EPS estimates using this Q1 run rate, adjusted for any seasonal factors and guidance management provides on the earnings call.
Metropolis Healthcare Q1 results FY27 vs Analyst Expectations
Whether the Metropolis Healthcare Q1 results FY27 met, beat, or missed analyst forecasts will determine how quickly institutional investors reposition their holdings.
Analyst estimates for the Metropolis Healthcare Q1 results FY27 varied ahead of the announcement. The actual revenue of Rs 372 Cr and PAT of Rs 50 Cr now set the benchmark against which FY27 consensus estimates will be revised. When a company beats on both revenue and profit, the stock typically sees buying in the first post-result session. A miss on both tends to trigger selling and downgrades. A mixed print stays range-bound until the earnings call provides clarity. Investors tracking Metropolis Healthcare should check live analyst verdict updates on the Univest Screener alongside the stock price movement to contextualise the post-result market reaction.
Metropolis Healthcare Dividend Update
No specific dividend announcement was confirmed as part of the Metropolis Healthcare Q1 results FY27 snapshot. Most companies declare dividends at the annual board meeting rather than with quarterly results. Investors tracking Metropolis Healthcare for its dividend yield should check the official NSE or BSE exchange filing, or the Univest Screener, for the latest record date and payout details.
Metropolis Healthcare Outlook After Q1 results FY27
The Metropolis Healthcare Q1 results FY27 establish the Q1 FY27 baseline for revenue at Rs 372 Cr and PAT at Rs 50 Cr. Whether FY27 ends up as a year of acceleration depends on two variables: whether the growth in revenue sustains through Q2 to Q4, and whether margin trends improve, stabilise, or deteriorate relative to this quarter’s gross profit margin of 17.5% . Management guidance on the earnings call will be the single most important datapoint for updating FY27 forecasts. Investors should also track macroeconomic inputs relevant to the healthcare sector through the rest of the year.
Investors tracking Metropolis Healthcare after the Q1 FY27 numbers should focus on three things heading into Q2 FY27: whether the growth in revenue sustains, whether the improvement trend in profit continues without the help of one-off items, and whether management’s guidance for FY27 holds. A results conference call or investor presentation, if scheduled, will be the primary opportunity for management to address these questions.
Should You Buy Metropolis Healthcare After the Q1 results FY27?
The question most investors ask after any quarterly result is whether it changes the investment case. The Metropolis Healthcare Q1 results FY27 show revenue of Rs 372 Cr, gross profit of Rs 65 Cr, and PAT of Rs 50 Cr. Whether these numbers justify buying, holding, or selling depends on the price the stock is trading at (Rs 584.5 at the time of this result), the FY27 consensus earnings estimate, and whether this Q1 run rate is sustainable for the remaining three quarters. Investors should check the P/E, P/B, and EV/EBITDA multiples on the Univest Screener against sector peers before deciding. This article is for educational purposes only and does not constitute investment advice. Please consult a SEBI-registered investment advisor before making any investment decision.
Metropolis Healthcare Share Price After the Q1 results FY27
Metropolis Healthcare shares traded at Rs 584.5 on the NSE, down 2.00% on the day the Metropolis Healthcare Q1 results FY27 were in focus. Post-result price moves are often driven by event-driven traders who have built positions ahead of the result and unwind them regardless of outcome. Investors should look past the first-session move and focus on whether the fundamental trend in revenue and earnings has changed. The 52 week high, 52 week low, and technical support levels for Metropolis Healthcare are available on the Univest Screener for investors who want to time their entry or exit.
Download the Univest iOS App or Univest Android App to track Metropolis Healthcare live share price and upcoming quarterly results.
Key Risks to Track After the Metropolis Healthcare Q1 results FY27
Investors should weigh these risks carefully before acting on the Q1 data.
1. Sector and Margin Risk
Metropolis Healthcare operates in the healthcare sector, which is exposed to occupancy levels, regulatory approvals and cost of medical talent. A reversal of the trends visible in the Metropolis Healthcare Q1 results FY27, particularly on the gross profit margin, could put the full-year FY27 earnings estimate at risk.
2. Single-Quarter vs Trend Risk
A single quarterly result can be distorted by working capital cycles, timing of receivables, or one-off costs and reversals that do not repeat. The Metropolis Healthcare Q1 results FY27 should be read alongside Q2 data before drawing firm conclusions.
3. Macro and External Risk
Macro factors including RBI rate decisions, INR/USD movements, input commodity prices, and rural versus urban demand mix can shift the environment in the healthcare sector faster than company-level actions can compensate for.
Conclusion
Investors researching the Metropolis Healthcare Q1 results FY27 will find the key numbers, revenue, gross profit, and net profit, summarised in the table above and analysed in each section of this article.
The Metropolis Healthcare Q1 results FY27 show standalone revenue of Rs 372 Cr (+15.03% year on year) and PAT of Rs 50 Cr (versus Rs 35 Cr in Q1 FY26). Gross profit came in at Rs 65 Cr at a margin of 17.5%, improving from Rs 49 Cr a year earlier. Revenue growth and a stronger bottom line were the two key themes of the quarter. Investors tracking Metropolis Healthcare should use the Metropolis Healthcare Q1 results FY27 as the baseline and watch Q2 FY27 results, due around October 2026, as the first confirmation of whether these trends are durable. Always consult a SEBI-registered advisor before acting on any quarterly result.
Disclaimer: Data and figures in this article are sourced from publicly available information. These may or may not be accurate. Please verify all data with the official NSE (nseindia.com) and BSE (bseindia.com) websites before making any investment decision. Investments in securities are subject to market risk. This content is for educational purposes only and is not investment advice by Univest (SEBI RA INH000013776).
Frequently Asked Questions on Metropolis Healthcare Q1 results FY27
What were the Metropolis Healthcare Q1 results FY27?
Ans. Metropolis Healthcare reported revenue of Rs 372 Cr (+15.03% YoY) and PAT of Rs 50 Cr for Q1 FY27 (quarter ended 30 June 2026), against Rs 35 Cr in Q1 FY26.
What is the PAT in the Metropolis Healthcare Q1 results FY27?
Ans. PAT in the Metropolis Healthcare Q1 results FY27 stood at Rs 50 Cr, compared with Rs 35 Cr in Q1 FY26, a change of +42.16%.
What was the revenue in the Metropolis Healthcare Q1 results FY27?
Ans. Revenue in the Metropolis Healthcare Q1 results FY27 was Rs 372 Cr, a change of +15.03% from Rs 323 Cr in Q1 FY26.
What was the gross profit in the Metropolis Healthcare Q1 results FY27?
Ans. Gross profit in the Metropolis Healthcare Q1 results FY27 was Rs 65 Cr (17.5% margin), compared with Rs 49 Cr in Q1 FY26, a change of +34.08%.
Did Metropolis Healthcare declare a dividend with the Q1 results FY27?
Ans. No dividend was confirmed as part of the Metropolis Healthcare Q1 results FY27 snapshot. Check the NSE or BSE exchange filing for the latest dividend announcement from Metropolis Healthcare.
What is the outlook for Metropolis Healthcare after Q1 results FY27?
Ans. Following the Metropolis Healthcare Q1 results FY27, analysts will track whether the growth in revenue and improvement in profit continue into Q2 FY27 (September quarter), along with margin trends and management guidance.
Is Metropolis Healthcare a good buy after Q1 results FY27?
Ans. The Metropolis Healthcare Q1 results FY27 show revenue of Rs 372 Cr and PAT of Rs 50 Cr. Investment decisions should be based on valuation relative to earnings trajectory, not a single quarter. Consult a SEBI-registered advisor before investing.
